Systematic Review of Real-World Data: Assessing Cancer, Major Adverse Cardiovascular Events, Venous Thromboembolism, Infection, and Mortality Risk Associated With JAK Inhibitors in Rheumatoid Arthritis Patients in the United States

Authors

Shadi Bazzazzadehgan, University of Mississippi
Chandler Gandy, University of Mississippi
Sebastian Bruera, Baylor University
Yinan Huang, University of Mississippi

Files

Description

Janus kinase inhibitors (JAKi) are novel oral therapy option for rheumatoid arthritis (RA) patients. However, data from the randomized controlled trials (RCTs) found an increased risk of cancer, serious cardiovascular events, blood clots, and death with JAKi. Patients enrolled in RCTs do not represent general patient population in real world. It is essential to complete the body of evidence with real-world data (RWD).

Publication Date

2-21-2024

Relational Format

poster

Recommended Citation

Bazzazzadehgan, Shadi; Gandy, Chandler; Bruera, Sebastian; and Huang, Yinan, "Systematic Review of Real-World Data: Assessing Cancer, Major Adverse Cardiovascular Events, Venous Thromboembolism, Infection, and Mortality Risk Associated With JAK Inhibitors in Rheumatoid Arthritis Patients in the United States" (2024). Annual Poster Session 2023-2024. 8.
https://egrove.olemiss.edu/pharm_annual_posters_2024/8